Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib with RICE in Pediatric Relapsed/Refractory DLBCL or MBCL
NCT03349346Phase 1Withdrawn
- Sponsor
- Gilead Sciences
- Start
- Jun 2019
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of idelalisib in diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) (2 cohorts), sponsored by Gilead Sciences. Primary endpoints: Incidence Rate of Dose Limiting Toxicities, Proportion of Participants Experiencing Adverse Events up to 12 months and 2 more. Planned start Jun 2019; status: withdrawn.
02
Drugs
idelalisib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT03349346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03349346.